Alzheimer’S Disease Treatment With Flashing Light
Alzheimer’s disease is one of the biggest unanswered questions in medicine.Five million Americans are currently estimated to have the mind-ravaging disease, a number expected to triple by 2050 without effective interventions. But the track record in drug that halts mental decline for Alzheimer’s Disease Treatment development has been terrible: a success rate of less than 1 percent.
“Already 1 of $5 of Medicare and Medicaid goes to Alzheimer’s,” said Rudy Tanzi, director of the genetics and aging Alzheimer’s disease research unit at Massachusetts General Hospital and a professor of neurology at Harvard Medical School.“As 71 million Baby Boomers like I head toward risk age, it will go into 1 of $3 or 1 of $2, and Alzheimer’s will single-handedly collapse our health-care system. It will single-handedly collapse Medicare and Medicaid in this country.”The need for Alzheimer’s disease treatment stands in stark contrast to science’s understanding of the disease.